About Evolva
Evolva is a Consumer company based in Reinach (Switzerland) founded in 2004, and was acquired by Lallemand in November 2023. Producer of natural and functional ingredients for food, beverage and healthcare products. Evolva has raised $67.27 million across 8 funding rounds from investors including Lallemand, European Union and Nice & Green. The company has 7 employees. Evolva has completed 3 acquisitions, including Allylix, ArpIda and Prosarix. Its chief executive, as recorded, is Murali Panchapagesa. Evolva offers products and services including Flavour and Fragrance Products and Newsletter Subscription. Its focus areas include Food and Agriculture, Food & Beverage Products, Multi-category and Consumer Goods. Its legal entity in India is Evolva Biotech Private Limited (U24230TN2005PTC076643).
Company details
The company was founded in 2004 in Reinach, Switzerland, and operates in the biotechnology sector focused on ingredients for food, beverages, and healthcare. Small molecule compounds are created and optimized through biosynthetic and evolutionary technologies, with production routes developed for sustainability. Operations emphasize natural and functional solutions, serving global markets in these industries.
- Headquarters Reinach, Switzerland
- Employees 7
- Stage Acquired
- SectorsConsumer
- Email••••••••
- Website evolva.com
- Social LinkedIn X
- Acquired by Lallemand (Nov 2023)
- Legal Name Evolva Biotech Private Limited
- Date of Incorporation 07 Feb, 2005
- Jurisdiction Chennai, Tamil Nadu, India
- Indian entity revenue₹57,246
FY 2020 · -98% YoY
- Indian entity net loss-₹2.8 Lakh
FY 2020 · -495% margin
- Indian entity EBITDA-₹2.8 Lakh
FY 2020 · -495% margin
- Total Equity Funding$67.27M (USD)
in 8 rounds
- Latest Funding Round$12.69M (USD), Post-IPO
Jan 2022
- InvestorsLallemand
& 12 more
- Employee Count7
- Investments & AcquisitionsAllylix
& 2 more
- Acquired byLallemand
(Nov 2023)
Associated legal entities of Evolva
Evolva operates through Evolva Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2020) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Evolva Biotech Private Limited CIN U24230TN2005PTC076643 | Active | 07 Feb 2005 | Chennai, Tamil Nadu | ₹0.0 Cr | 7 | 3 | View details |
Products & Services of Evolva
Evolva offers a comprehensive portfolio of products and services, including Flavour and Fragrance Products and Newsletter Subscription.
Sustainable ingredients for food and beverage applications
Platform for updates on products and industry news
Funding Insights of Evolva
Evolva has successfully raised a total of $67.27M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $12.69 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.27M
- Total Rounds 8
- Last Round Post-IPO — $12.69M
- First Round $15.07M
(Aug 2004)
- Investors Count 12
All 8 funding rounds of Evolva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $12.69M | Post-IPO | – | – | |
| Nov 2021 | $8.11M | Post-IPO | – | – | |
| Nov 2017 | $86.22M | Post-IPO | – | – | – |
| Dec 2016 | Grant | – | – | ||
| Jan 2010 | $20.31M | Post-IPO | – | – | – |
| Oct 2009 | $42.27M | Series B | – | Auriga Partners, Aravis | |
| Dec 2006 | $9.93M | Series A | – | – | |
| Aug 2004 | $15.07M | Series A | – | – |
13 investors in total: 13 institutional.
Investors in Evolva
Evolva has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Lallemand, European Union and Nice & Green.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | veraison.ch | Zurich, Switzerland | ||
Investments are made in early-stage healthcare startups. | wellington-partners.com | Munich, Germany | ||
Private equity investments are directed toward multiple sectors. | aurigapartners.net | Los Angeles, United States | ||
| astellasventure.com | ||||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark | ||
Growth capital is provided by Aravis for Swiss high-tech companies. | aravis.ch | Switzerland | ||
Venture capital investments are managed by Auriga Partners in France. | 1998 | aurigapartners.com | Paris, France | |
Finance services are provided by Nice & Green in Switzerland. | 2017 | nicengreen.ch | Nyon, Switzerland | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Evolva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Evolva Biotech Private Limited (Evolva)
Evolva Biotech Private Limited is the primary company behind Evolva. The board of Evolva Biotech Private Limited currently have 3 directors; the longest-serving is Shriram, appointed in 2018. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shriram DIN 07896350 | Director | 27 Feb 2018 | 8 yrs 8 mo | Evolva Biotech Private Limited |
| Alessandro Mauro Del Fabro DIN 08302141 | Additional Director | 13 Dec 2018 | 7 yrs 11 mo | Evolva Biotech Private Limited |
| Anandmohan Harendra Maurya DIN 08112700 | Additional Director | 13 Dec 2018 | 7 yrs 11 mo | Evolva Biotech Private Limited |
People of Evolva
15 people are tracked at Evolva (10 in leadership, 5 in board & advisors); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Murali Panchapagesa | CEO & MD | Leadership |
Carsten Däweritz | CFO | Leadership |
Anne De Vos | Chief Commercial Officer | Leadership |
Astrid Schäfer | Head of R&D | Leadership |
Gerhard Lobmaier | COO | Leadership |
Dr. Gerhard Lobmaier | Chief Operating Officer | Leadership |
Jean-Philippe Meyer | Vice President Regulatory Affairs | Leadership |
Norbert Bender | CMO | Leadership |
Mathis Heuss | Head Of Business Finance | Leadership |
Alessandra Batelli | Sr Director Business Development | Leadership |
Andreas Pfluger | Board Member | Board & advisors |
Beat In-Albon | Chairman | Board & advisors |
Andreas Weigelt | Board Member | Board & advisors |
Stephan Schindler | Board Member | Board & advisors |
Christoph Breucker | Board Member | Board & advisors |
Complete people profiles for Evolva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Evolva
Figures of Evolva Biotech Private Limited, the primary company behind Evolva, for FY 2020. Revenue was ₹57,246 (-98% year on year). Net loss was -₹2.8 Lakh (-495% margin). EBITDA was -₹2.8 Lakh (-495% margin). Revenue has grown at a compounded annual rate of -93% over three years and -79% over five years.
- ₹57,246Revenue · FY 2020 · -98% YoY
- -₹2.8 LakhNet loss · -495% margin
- -₹2.8 LakhEBITDA · -495% margin
- ₹1.7 LakhPaid-up capital
- 7Employees (provident fund records)
- -93%Revenue CAGR, 3 years
- -79%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Evolva Biotech Private Limited are on its company page.
Detailed financial statements for Evolva
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evolva
Evolva has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Allylix, ArpIda and Prosarix.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Flavoring ingredients are produced from plants via yeast fermentation. | allylix.com | United States | 2002 | Nov 2014 | $61.7M | |
Computational drug discovery company with proprietary platform for small molecule screening and design | prosarix.com | Cambridge, United Kingdom | 2006 | Aug 2014 | $1.2M | |
Drugs for treating microbial resistance are developed by the company. | arpida.com | Reinach, Switzerland | 1997 | Sep 2009 | •••• |
Complete acquisition details for Evolva
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Evolva
8 dated milestones of Evolva across 19 years, from founding to its latest funding, stage changes and deals.
Web traffic of Evolva
The website of Evolva (evolva.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 125.2% vs previous month
Websites whose visitors overlap most with Evolva. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sysbio.se | 100% | #5,708,709 | View details | ||
glowingplant.com | glowingplant.com | 98% | – | ||
| bbi-biotech.com | 58% | 2.3K | #6,883,516 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evolva
Complete news archive for Evolva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evolva
Evolva was founded in 2004.
Evolva is headquartered in Reinach, Switzerland. It is registered at Reinach, Basel-landschaft, Switzerland.
Murali Panchapagesa is the CEO of Evolva, as recorded in our data.
Evolva is a funded company, having raised a total of $67.27M across 8 funding rounds to date. The company's 1st funding round was a Series A of $15.07M, raised on Aug 2004.
Evolva has 7 employees.
The primary company behind Evolva, Evolva Biotech Private Limited, reported revenue of ₹57,246 for FY 2020, down 98% year on year.
The company was founded in 2004 in Reinach, Switzerland, and operates in the biotechnology sector focused on ingredients for food, beverages, and healthcare. Small molecule compounds are created and optimized through biosynthetic and evolutionary technologies, with production routes developed for sustainability. Operations emphasize natural and functional solutions, serving global markets in these industries.
Evolva offers Flavour and Fragrance Products and Newsletter Subscription.
Evolva has 13 investors. Key investors include Lallemand, European Union, Nice & Green, VERAISON Capital, and Wellington Partners Venture Capital.
Evolva operates through Evolva Biotech Private Limited.
Yes. Evolva was acquired by Lallemand in November 2023.